Clinical trials: Hepatitis B Chronic Infection
Hepatitis B, Chronic Hepatitis B
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection
- Trial name
- NCT02826018
- Testing
- ALN-HBV, Sterile Normal Saline (0.9% NaCl)
- Where
- 9 sites in Australia, Hong Kong and 4 more
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Chronic Hepatitis B
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects
- Trial name
- NCT03662568
- Testing
- GLS4, RTV, ETV
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis B, Chronic
A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
This is a prospective observational study of CHB patients who have not received antiviral treatment but HBV DNA are positive.Investigators aim to explore the antiviral effect and influencing factors of patients over 30 years old…
- Conditions
- Hepatitis B, Chronic, Treatment
- Trial name
- NCT07637214
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Hepatitis B, Chronic
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B
This is a prospective, multicentre observational study of Chronic Hepatitis B （CHB）in different clinical stages. We intend to compare the immune status of various types of CHB patients, and we propose to establish a staging and…
- Trial name
- NCT06525909
- Where
- 5 sites in China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Chronic Hepatitis B
A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B
The purpose of this study is to evaluate the safety and tolerability of JNJ-440 in healthy and Chronic Hepatitis B (CHB) participants after single and multiple doses; and to evaluate the pharmacokinetic (PK) of JNJ-440 in healthy…
- Trial name
- NCT03439488
- Testing
- JNJ-440
- Where
- 7 sites in Moldova, New Zealand and 3 more
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatic Failure, Hepatic Impairment
Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects
The objective was to determine if hepatitis C virus (HCV) infection or mild to severe hepatic impairment (Child-Pugh Classes A, B, and C) altered the PK of buprenorphine, norbuprenorphine, or naloxone.
- Conditions
- Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
- Trial name
- NCT01846455
- Testing
- 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Hepatitis B, Chronic
Study of Safety and Tolerability of DCR HBVS
DCR-HBVS will be evaluated for safety and efficacy in healthy volunteers and chronic hepatitis B patients.
- Trial name
- NCT03772249
- Testing
- DCR-HBVS
- Where
- 9 sites in Australia, Hong Kong and 3 more
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Chronic Hepatitis B
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
This is the first in human study of 162, and the primary objective is to evaluate the safety and tolerability of 162 with a single ascending dose in healthy adult subjects.
- Trial name
- NCT05310487
- Testing
- 162
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yangshengtang Co., Ltd
Hepatitis B, Chronic Hepatitis B
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
This is an open-label, randomized, multi-part study to evaluate the relative oral bioavailability of a tablet formulation of AL-3778 (formerly NVR 3-778) administered under fasted and fed conditions (Parts 1 and 2) and the…
- Conditions
- Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
- Trial name
- NCT03032536
- Testing
- AL-3778, Entecavir, Tenofovir disoproxil fumarate
- Where
- 2 sites in New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Chronic Hepatitis B
GLS4/RTV and TAF Drug-drug Interaction
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.
- Trial name
- NCT04551261
- Testing
- GLS4, RTV, TAF
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis b
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects.
- Trial name
- XT1061 (NCT06280534)
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Hepatocellular Carcinoma, Hepatitis B
Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population
Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally.
- Trial name
- NCT06379334
- Testing
- Urine test
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Chronic Hepatitis B
Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance
Achieving a functional cure for chronic hepatitis B (CHB) is largely hindered by the irreversible functional exhaustion and immune tolerance of hepatitis B virus (HBV)-specific CD8 positive T (CD8+ T) cells.
- Trial name
- NCT07777250
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Municipal Administration of Hospitals
Hepatitis B
HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B
This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected…
- Trial name
- NCT01298037
- Where
- 12 sites in United States, Canada
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Chronic Hepatitis B
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
The goal of this clinical trial is to learn if ALG-000184 is safe, well-tolerated, and works to treat chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT04536337
- Testing
- ALG-000184, Entecavir
- Where
- 10 sites in Australia, China and 4 more
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Chronic Hepatitis B
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB
The anti-virus effects is not satisfying in some of Chronic Hepatitis B（CHB) patients who have been on anti-Hepatitis B Virus (HBV) drugs therapy.
- Trial name
- CTHBVACADCHB (NCT02615639)
- Testing
- HPDC-T cells & Entecavir, Entecavir, HPDC-T cells & IFN-a-2a
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis B Virus Infection
A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EDP-721 in healthy subjects.
- Trial name
- NCT04971512
- Testing
- EDP-721, EDP-721 (Part 2), EDP-514
- Where
- New Zealand
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Chronic Hepatitis B
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses.
- Trial name
- NCT05717686
- Testing
- AHB-137 injection
- Where
- 9 sites in United States, Hong Kong and 2 more
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AusperBio Therapeutics Inc.
HBV Infection, Chronic Hepatitis B
Population-wide Research for HBV-related Liver Diseases in Maoming City
Hepatitis B virus (HBV) infection is a major public health problem and chronic HBV infection affects about 296 million people worldwide and is the leading etiology of cirrhosis and hepatocellular carcinoma globally.
- Conditions
- HBV Infection, Chronic Hepatitis B, Cirrhosis, HCC
- Trial name
- PreMAO (NCT06184347)
- Testing
- Rapid tests for HBsAg
- Volunteers
- 3,700,000 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris